TROP2-Targeted ADC Shows Promise for TNBC Treatment
Okay, here’s a breakdown of the key facts from the provided text, focusing on the drug DB-1305/BNT325 and it’s clinical trial data:
Drug: DB-1305/BNT325 (a TROP2-targeted antibody-drug conjugate – ADC)
Key Findings from the Trial (in patients with 3rd-line+ metastatic triple-negative breast cancer – TNBC):
* Objective Response Rate (ORR): 34.6% (95% CI, 17.21-55.67)
* Disease Control Rate (DCR): 80.8% (95% CI, 60.65-93.45)
* Adverse Events: All 26 patients experienced treatment-related adverse events.
* Grade 3 or higher events occured in 34.6% of patients (9/26).
* One patient discontinued treatment due to adverse events.
* Common adverse events: stomatitis, anemia, nausea, decreased neutrophils and white blood cells.
Critically important Context & Additional Information:
* Payload & Linker: DB-1305/BNT325 uses a DNA topoisomerase-1 payload and a cleavable linker.This is similar to other TROP2-targeting ADCs like sacituzumab govitecan and datopotamab deruxtecan.
* Drug-to-Antibody Ratio (DAR): 4
* Patient Population:
* The trial was conducted in both the US and China, but the majority of patients were enrolled in China and were of Asian descent.
* Patients had a generally good performance status (ECOG 1, meaning they are ambulatory and more than 50% of the time are up and about).
* Ongoing Research: DB-1305/BNT325 is currently being evaluated in combination with BNT327, an investigational anti-PD-L1/VEGF-A bispecific antibody. The combination is also being studied in the US.
* Safety Profile: The safety profile of ADCs can vary significantly between drugs, despite targeting similar mechanisms.
In essence, the text presents early clinical data suggesting DB-1305/BNT325 shows promising activity in heavily pre-treated TNBC, but highlights the need for further study in more diverse patient populations.